Last reviewed · How we verify
Viaject 7
Viaject 7 is a recombinant human insulin analog.
Viaject 7 is a recombinant human insulin analog. Used for Diabetes treatment.
At a glance
| Generic name | Viaject 7 |
|---|---|
| Sponsor | Biodel |
| Drug class | insulin analog |
| Target | insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of natural insulin in the body, helping to lower blood sugar levels. This is achieved through the binding of insulin to its receptor, which triggers a cascade of downstream effects that ultimately lead to the uptake of glucose by cells.
Approved indications
- Diabetes treatment
Common side effects
- Hypoglycemia
Key clinical trials
- Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants (PHASE1)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- MiniMed Fit Payload Wear Study
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis (NA)
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viaject 7 CI brief — competitive landscape report
- Viaject 7 updates RSS · CI watch RSS
- Biodel portfolio CI